Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (6599)	6/20/2002 9:02:34 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 52153

Peter, Play bit with numbers (subgroups), and again data are far from very solid. At least they are far from what I was expecting for IL1/IL18 blockade. JB and VRTX are good when presenting data that are in their advance. Where are numbers for MTX<6 months (17%), for no DMARD (17%, p=0.08), for baseline median RA activity number. Delta ARC20 (~20) means very little, and absolute ACR20 or delta ACR20 can not be compared with Enbrel, Ramicade or Kineret results. Yes, those results are at 12 weeks period, but where are data for 4 and 8 weeks? To see how are pts doing in time? Regards the corticosteroid sparing, you have 7/16/21 pts (pts with ACR20 response and on steroid, 7/55= 13%, 21/109 = 20%), so you can draw your own conclusion! Other medications pts were on? Yes, OA may be good indication for P. However, before getting excited (I was burned two times from VRTX IR machine) let first see PIIa results. Miljenko

To: Biomaven who wrote (6599)	6/22/2002 1:10:13 AM
From: sammaster	Respond to of 52153

anyone know what the "bottom" was for biotech valuation in mid 1998 before the great bubble.... were valuations at bottom when they are 2 times cash like i have heard or 2 times net cash(subtract debt)? seems like all biotechs would have debt at early stages but now we have a few biotechs with huge net cash even subtracting debt and also with products in pipeline sellin at net cash value.... seems like this low valuation even lower than previous biotech bears? true?